SG11202100126QA - 4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer - Google Patents

4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer

Info

Publication number
SG11202100126QA
SG11202100126QA SG11202100126QA SG11202100126QA SG11202100126QA SG 11202100126Q A SG11202100126Q A SG 11202100126QA SG 11202100126Q A SG11202100126Q A SG 11202100126QA SG 11202100126Q A SG11202100126Q A SG 11202100126QA SG 11202100126Q A SG11202100126Q A SG 11202100126QA
Authority
SG
Singapore
Prior art keywords
pyridine
treating cancer
substituted pyrrolo
modulators useful
erbb
Prior art date
Application number
SG11202100126QA
Other languages
English (en)
Inventor
Carsten Schultz-Fademrecht
Bert Klebl
Peter Nussbaumer
Carsten Degenhart
Matthias Baumann
Original Assignee
Lead Discovery Center Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Discovery Center Gmbh filed Critical Lead Discovery Center Gmbh
Publication of SG11202100126QA publication Critical patent/SG11202100126QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202100126QA 2018-08-23 2019-08-23 4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer SG11202100126QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18190603.3A EP3613738A1 (en) 2018-08-23 2018-08-23 4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer
PCT/EP2019/072564 WO2020039060A1 (en) 2018-08-23 2019-08-23 4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer

Publications (1)

Publication Number Publication Date
SG11202100126QA true SG11202100126QA (en) 2021-02-25

Family

ID=63442398

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100126QA SG11202100126QA (en) 2018-08-23 2019-08-23 4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer

Country Status (12)

Country Link
US (1) US20220370440A1 (es)
EP (2) EP3613738A1 (es)
JP (1) JP2022512536A (es)
KR (1) KR20210049096A (es)
CN (1) CN112585138A (es)
AU (1) AU2019324528A1 (es)
BR (1) BR112021002986A2 (es)
CA (1) CA3105010A1 (es)
IL (1) IL280661A (es)
MX (1) MX2021002109A (es)
SG (1) SG11202100126QA (es)
WO (1) WO2020039060A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3868759A1 (en) * 2020-02-20 2021-08-25 PearlRiver Bio GmbH 2,3,5-substituted pyrrolo[2,3-b]pyridines as erbb modulators useful for treating cancer
EP3868760A1 (en) * 2020-02-20 2021-08-25 PearlRiver Bio GmbH 2,3,5-substituted pyrrolo[2,3-b]pyridines as erbb modulators useful for treating cancer
WO2022033416A1 (zh) * 2020-08-10 2022-02-17 上海和誉生物医药科技有限公司 作为egfr抑制剂的稠环化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2440559B1 (en) * 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
WO2011075613A1 (en) * 2009-12-18 2011-06-23 Sanofi Azaindole derivatives, their preparation and their therapeutic application
ES2619585T3 (es) * 2010-03-22 2017-06-26 Lead Discovery Center Gmbh Derivados de triazina disustituidos farmacéuticamente activos
JP6353788B2 (ja) * 2012-01-13 2018-07-04 エイシア バイオサイエンシーズ インコーポレイテッド 抗がん剤としての複素環式化合物およびその使用
CN103748096B (zh) * 2012-08-06 2017-10-20 美国艾森生物科学公司 作为蛋白激酶抑制剂的吡咯并嘧啶化合物
CN104860941B (zh) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
EP3143015B1 (en) * 2014-05-13 2019-02-20 ARIAD Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
AU2016209046A1 (en) * 2015-01-23 2017-07-20 Aclaris Therapeutics, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
AU2016220219B2 (en) * 2015-02-17 2020-05-14 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2017066193A1 (en) * 2015-10-15 2017-04-20 Princeton Drug Discovery, Llc Novel inhibitors of protein kinases
CN106946896B (zh) * 2017-03-30 2019-05-21 成都知普莱生物医药科技有限公司 呋喃并[2,3-d]嘧啶-4-胺衍生物

Also Published As

Publication number Publication date
EP3807274A1 (en) 2021-04-21
IL280661A (en) 2021-03-25
BR112021002986A2 (pt) 2021-05-11
MX2021002109A (es) 2021-04-28
JP2022512536A (ja) 2022-02-07
AU2019324528A1 (en) 2021-01-28
CA3105010A1 (en) 2020-02-27
CN112585138A (zh) 2021-03-30
US20220370440A1 (en) 2022-11-24
WO2020039060A1 (en) 2020-02-27
KR20210049096A (ko) 2021-05-04
EP3613738A1 (en) 2020-02-26
EP3807274B1 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
IL277576A (en) Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
HK1258905A1 (zh) 作為ret激酶抑制劑的取代的吡唑並[1，5-a]吡啶化合物
HK1248675A1 (zh) 調節激酶的1h 吡咯並[2，3-b]吡啶衍生物的合成
IL280661A (en) PYRROLO[2,3-B]PYRIDINE is mutated at position 4 as ERBB regulators that are useful in cancer therapy
IL253284B (en) History of 4h-pyrrolo[2,3-c]pyridine-4-one
IL283149A (en) Inhibitors of HPK1 and their use in the treatment of cancer
PL3419978T3 (pl) Pirazolo[1,5-a]pirazyn-4-ylowe pochodne jako inhibitory JAK
EP3380475A4 (en) OCTAHYDROPYRROLO [3,4-C
IL257413A (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
ZA201406788B (en) 6-(4-(1-amino-3-hydroxycyclobutyl)phenyl)-5-phenyl(furo,thieno or pyrrolo)[2,3-d]pyrimidin-4-one derivatives for the treatment of cancer
EP3931564A4 (en) METHODS OF TREATMENT OF MAP3K8 POSITIVE TUMORS
HK1259613A1 (zh) 新型5h-吡咯並[2，3-d]嘧啶-6(7h)-酮衍生物
IL260536B (en) Compounds 6,7-Dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide
EP4010305A4 (en) PROCESS FOR MANUFACTURE OF TREATED MANURE
HUE063830T2 (hu) Eljárás 3,6-diszubsztituált imidazo[1,2-b]piridazin származék elõállításához
IL280122A (en) Imidazo[2,1-B]pyridazine derivatives as TRK inhibitors
EP4048284A4 (en) METHOD FOR TREATING CANCER
AU2019902841A0 (en) Methods for producing treated manure
SG11202101060WA (en) Bicyclic compounds as kinase modulators, methods and uses thereof
ZA201801639B (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials